In a significant development for the medical technology sector, Royal Philips has announced the appointment of its Chief Medical Officer, Dr. Carla Goulart Peron, to the Board of Directors of the Medical Device Innovation Consortium (MDIC). This strategic move strengthens the partnership between regulatory bodies and industry leaders in advancing healthcare innovation.
A Strategic Appointment for Medical Device Innovation
The Medical Device Innovation Consortium, established in 2012 as a unique public-private partnership, brings together stakeholders across the medical device spectrum with the US Food and Drug Administration and other agency partners. The organization's primary mission is to accelerate patient access to innovative medical technologies through collaborative efforts that streamline regulatory processes and inform coverage decisions.
Leadership Perspectives on the Appointment
Andrew C. Fish, President and CEO of MDIC, expressed enthusiasm about the new appointment, stating: "We are delighted to welcome Carla to MDIC's Board of Directors. She brings deep experience bridging clinical evidence and innovation that will strengthen our work, and we look forward to her insights and strategic guidance."
Dr. Peron responded with equal enthusiasm about her new role: "As a leading innovator in healthcare, Philips shares MDIC's mission to improve health and save lives by accelerating access to medical technologies. MDIC creates a trusted space where government agencies and medical device manufacturers collaborate to streamline the regulatory process and inform coverage decisions – all to deliver safe and effective medical devices to patients. I am honored to be appointed to MDIC's leadership team and contribute to their important work."
MDIC's Critical Role in Healthcare Innovation
The Medical Device Innovation Consortium operates across three critical domains: medical device quality, evidence development, and digital health advancement. The organization develops comprehensive research, practical toolkits, and actionable frameworks that help manufacturers navigate complex regulatory approval processes while maintaining the highest quality standards.
MDIC serves as a unique nexus where FDA representatives and medical device manufacturers collaborate as peers alongside patients, clinicians, and other key stakeholders. This pre-competitive environment provides a trusted space to address fundamental scientific and technical challenges that shape the future of medical device innovation.
Dr. Peron's Qualifications and Philips' Commitment
As Chief Medical Officer at Royal Philips, Dr. Carla Goulart Peron leads the company's global medical and scientific organization while overseeing Philips' comprehensive medical strategy. Her primary responsibility involves ensuring that Philips' innovations remain grounded in clinical evidence, scientific standards, and patient safety protocols.
Across Philips' diverse business units, Dr. Peron and her team provide essential medical leadership in multiple critical areas including medical safety protocols, medical affairs management, health economics and outcomes research, clinical research initiatives, and strategic clinical partnerships. Their work focuses on translating scientific insights into practical technologies that deliver measurable improvements in patient outcomes and healthcare value.
Dr. Peron brings more than fifteen years of leadership experience in the medical technology industry and broader healthcare sector to her new role. Her background includes deep clinical expertise and a hands-on approach to building highly engaged multidisciplinary teams capable of addressing complex healthcare challenges.
Royal Philips has demonstrated a strong commitment to meaningful innovation through its dedication to advancing regulatory science, strengthening quality systems, and fostering collaboration across the healthcare ecosystem. The company's participation in organizations like MDIC reflects its broader mission to help provide better care for more people through technological advancement and evidence-based approaches to healthcare delivery.
